VRTXVertex Pharmaceuticals

$510.18+32% 1Y

$510.18

$376.6252 weeks$558.12

VRTX in its own filings

Nothing in VRTX's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

525

Events found in the filings · across 3,644 filings · the record starts in 1996

Hard flags: none
Hard flags
Most recent filing: Sep 1, 2026
Most recent filing · Form 8-K
Record starts: May 14, 1996
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 2, 2026
Change in certifying accountanthistorical: 2005-09-07
Material impairment2 occurrences: 2017-10-25
SEC comment-letter activity66 occurrences: 2026-04-14

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Sep 1, 2026On August 27, 2026, Vertex Pharmaceuticals Incorporated (the “Company”) appointed Jonathan Poole as Executive Vice President and Chief Financial Officer of the Company, effective January 1, 2027 (the “Effective Date”)Director or officer change · Form 8-K
Aug 3, 2026Vertex Reports Second Quarter 2026 Financial Results.Earnings release · press release
Jul 7, 2026Merger Agreement On July 6, 2026, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“Parent”), Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Agreement …Material agreement entered · Form 8-K
May 13, 2026Departure of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer On March 27, 2026, the Board of Directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") approved the Vertex Pharmaceuticals Incorporated …Director or officer change · Form 8-K
May 4, 2026Vertex Reports First Quarter 2026 Financial Results.Earnings release · press release
Apr 29, 2026On April 28, 2026, Suketu Upadhyay informed the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”) of his decision not to stand for re-election as a director of the Company at the Company’s 2026 annual meeting of shareholders (the “2026 Annual Meeting”)Director or officer change · Form 8-K
Mar 31, 2026Vertex Pharmaceuticals Incorporated (the “Company”) has completed the submission to the U.S. Food and Drug Administration (the “FDA”) of its rolling Biologics Licensing Application (“BLA”) for potential accelerated approval of povetacicept for the treatment of immunoglobulin A nephropathy (“IgAN”) in adults.Other event · Form 8-K
Feb 12, 2026Vertex Reports Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
Nov 3, 2025Vertex Reports Third Quarter 2025 Financial Results.Earnings release · press release